Trial reportPsychopharmacology2009
Further evidence of association between amphetamine response and SLC6A2 gene variants.
Trial report in Psychopharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 49 citations in OpenAlex.
- No major role of norepinephrine transporter gene variations in the cardiostimulant effects of MDMA.European journal of clinical pharmacology · 2018Trial
- Pharmacogenetics of stimulant abuse liability: association of CDH13 variant with amphetamine response in a racially-heterogeneous sample of healthy young adults.Psychopharmacology · 2017Trial
- Candidate gene studies of a promising intermediate phenotype: failure to replicate.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2013Trial
- Network analysis of the genomic basis of the placebo effect.JCI insight · 2017Article
- Temperament and externalizing behavior as mediators of genetic risk on adolescent substance use.Journal of abnormal psychology · 2016Article
- Susceptibility loci for heroin and cocaine addiction in the serotonergic and adrenergic pathways in populations of different ancestry.Pharmacogenomics · 2015Article
- Article
- Genetic factors modulating the response to stimulant drugs in humans.Current topics in behavioral neurosciences · 2012Review
- Psychopathological aspects of dopaminergic gene polymorphisms in adolescence and young adulthood.Neuroscience and biobehavioral reviews · 2011Review
- OPRM1 gene variants modulate amphetamine-induced euphoria in humans.Genes, brain, and behavior · 2011Article
- Monoamine transporters: vulnerable and vital doorkeepers.Progress in molecular biology and translational science · 2011Review
- Involvement of threonine 258 and serine 259 motif in amphetamine-induced norepinephrine transporter endocytosis.Journal of neurochemistry · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
background and rationaleWe previously found that the intronic norepinephrine transporter gene (SLC6A2) polymorphism rs36017 modulates feelings of elation after administration of 20 mg D-amphetamine in healthy volunteers.
objectivesIn this study, we further investigated the association between D-amphetamine response and 11 SLC6A2 single-nucleotide polymorphisms (SNPs), including rs36017, in an extended sample of Caucasian young adults.
methodsOne hundred fifty-nine healthy volunteers participated in a three-session double-blind crossover design receiving either placebo or oral D-amphetamine (10 and 20 mg). Based on our previous results, we examined the associations between levels of self-reported elation and vigor after D-amphetamine administration and SNPs and SNP haplotypes in SLC6A2.
resultsConsistent with our previous findings, SNPs rs36017 and rs1861647 were associated with significantly higher ratings of elation and vigor after 20 mg Damphetamine. Ratings of vigor after 20 mg D-amphetamine were also associated with a two-SNP haplotype formed with rs1861647 and rs5569 and a three-SNP haplotype formed with rs36017, rs10521329, and rs3785155.
conclusionsThese results provide further evidence that genetic variants in the SLC6A2 gene are involved in acute response to D-amphetamine, which may influence progression to amphetamine abuse. Identifying sources of variation in acute drug responses could lead to better prevention and treatment of psychostimulant abuse and may be valuable in the therapeutic use of stimulants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.